These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17382152)

  • 1. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications.
    Freedland SJ; Kane CJ; Amling CL; Aronson WJ; Terris MK; Presti JC;
    Urology; 2007 Mar; 69(3):495-9. PubMed ID: 17382152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database.
    Turley RS; Hamilton RJ; Terris MK; Kane CJ; Aronson WJ; Presti JC; Amling CL; Freedland SJ;
    J Urol; 2008 Feb; 179(2):523-7; discussion 527-8. PubMed ID: 18076952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
    Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
    Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR; McNeal JE; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
    Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
    Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database.
    Turley RS; Terris MK; Kane CJ; Aronson WJ; Presti JC; Amling CL; Freedland SJ;
    BJU Int; 2008 Nov; 102(9):1074-9. PubMed ID: 18778348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?
    Smith EB; Frierson HF; Mills SE; Boyd JC; Theodorescu D
    Cancer; 2002 Apr; 94(8):2282-7. PubMed ID: 12001128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.
    Scott S; Samaratunga H; Chabert C; Breckenridge M; Gianduzzo T
    BJU Int; 2015 Oct; 116 Suppl 3():26-30. PubMed ID: 26260531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.
    Epstein JI; Feng Z; Trock BJ; Pierorazio PM
    Eur Urol; 2012 May; 61(5):1019-24. PubMed ID: 22336380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
    Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
    World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.
    Chun FK; Briganti A; Shariat SF; Graefen M; Montorsi F; Erbersdobler A; Steuber T; Salonia A; Currlin E; Scattoni V; Friedrich MG; Schlomm T; Haese A; Michl U; Colombo R; Heinzer H; Valiquette L; Rigatti P; Roehrborn CG; Huland H; Karakiewicz PI
    BJU Int; 2006 Aug; 98(2):329-34. PubMed ID: 16879673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
    Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
    J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
    Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.